Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Thrombosis in pregnancy and cancer

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Maternal or cancer-associated unstable PE

Shock, severe hypoxaemia, syncope, right-heart failure or a threatened limb requires immediate senior multidisciplinary care; pregnancy or cancer must not delay diagnostic imaging or reperfusion assessment.

Action: Use ABCDE assessment, start the appropriate therapeutic parenteral anticoagulant when bleeding risk permits, obtain urgent imaging, involve obstetrics and anaesthesia or oncology and haematology, and activate thrombolysis, thrombectomy, embolectomy or vascular pathways for haemodynamic or limb threat.

Synopsis

Diagnose and treat thrombosis safely when pregnancy, postpartum physiology or active cancer changes presentation, anticoagulant choice, duration, procedures and bleeding risk.

  • Pregnancy and cancer raise VTE probability but symptoms still require objective imaging; do not use D-dimer or a non-validated score alone to dismiss a clinically suspected event.
  • Therapeutic LMWH is first-line treatment for most pregnancy-associated DVT or PE because it does not cross the placenta and has extensive obstetric experience.
  • Continue pregnancy-associated VTE treatment for the remainder of pregnancy and at least 6 weeks postpartum, with at least 3 months total therapy.
  • Warfarin and DOACs are generally avoided for treating VTE during pregnancy; warfarin is compatible with breastfeeding, whereas DOACs are not routinely recommended during breastfeeding.
  • Plan delivery and neuraxial timing jointly: therapeutic LMWH is normally withheld for at least 24 hours before planned neuraxial procedures, with exact timing set by obstetric anaesthesia protocol.
  • For active cancer-associated proximal DVT or PE, NICE recommends anticoagulation for 3–6 months then review; continue beyond this while cancer activity, treatment and recurrence risk justify it.
  • Apixaban or rivaroxaban is an option for many adults with active cancer, but gastrointestinal or genitourinary lesions, interactions, vomiting, organ dysfunction and bleeding can favour LMWH.
  • Thrombocytopenia requires specialist intensity and transfusion decisions based on clot acuity, location, platelet trend and bleeding; do not use a universal unsupervised platelet cutoff.
  • A functioning, well-positioned and uninfected catheter associated with thrombosis can often remain while therapeutic anticoagulation is given; remove it if unnecessary, infected or malfunctioning.
  • Incidental PE requires radiology confirmation and clot-burden-specific specialist review.

Key red flags

Sudden dyspnoea, syncope, hypotension, chest pain or hypoxaemia in pregnancy, postpartum or cancer is possible PE and requires urgent objective assessment rather than attribution to physiology or malignancy.

Pelvic, iliac or inferior vena cava thrombosis can present with whole-leg swelling, back, buttock or abdominal pain and may be missed by a limited proximal leg ultrasound.

Active bleeding, placenta praevia, recent intracranial disease, severe thrombocytopenia, tumour invasion, neuraxial catheter or imminent delivery profoundly alters anticoagulation timing and needs senior coordination.

Recurrent thrombosis on treatment requires adherence, dose, interactions, HIT, cancer progression and APS assessment rather than an unexamined switch to a lower dose.

Investigation priorities

01
First-line pregnancy DVT imaging: compression ultrasoundFirst stepFirst line

Confirm proximal lower-limb thrombosis without ionising radiation.

Management branches

Suspected pregnancy VTEAnticoagulate and image promptly

Pregnant or postpartum patient has clinical features of DVT or PE.

  1. Assess stability, bleeding and delivery context and begin therapeutic LMWH while arranging imaging if delay is expected and no contraindication exists.
  2. Use compression ultrasound for leg symptoms and a chest X-ray-guided V/Q or CTPA pathway for suspected PE.
  3. If confirmed, agree LMWH dose, delivery and neuraxial plan and continue through at least 6 weeks postpartum and 3 months total.

Key medicines

Enoxaparin in pregnancy-associated VTEA common therapeutic regimen is 1 mg/kg subcutaneously every 12 hours, using the weight rule in the obstetric protocol; continue for the remainder of pregnancy and at least 6 weeks postpartum, with at least 3 months total.Adjust or monitor in renal impairment and selected weight extremes. Coordinate delivery and neuraxial timing, review platelets and bleeding and use UFH when very rapid offset is needed. Do not give with suspected HIT.
Apixaban for cancer-associated VTEGive 10 mg orally twice daily for 7 days then 5 mg twice daily; after 6 months, any move to 2.5 mg twice daily must follow an individual extended-treatment decision rather than automatic reduction in active cancer.Review luminal gastrointestinal or genitourinary lesions, thrombocytopenia, vomiting, CYP3A4/P-gp interactions, renal and liver function and procedures. Avoid during pregnancy and breastfeeding; use specialist guidance for brain tumours or very low platelets.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • RCOG Green-top 37b acute thromboembolic diseaseUK pregnancy VTE investigation, LMWH treatment, duration and delivery considerations.
  • RCOG Green-top 37a thrombosis risk reductionUK antenatal and postpartum risk context and prophylaxis.
  • NICE NG158 VTE recommendationsCancer-associated treatment selection and 3–6-month review.
  • British Society for Haematology cancer-associated thrombosis guidelineUK cancer-specific anticoagulant, thrombocytopenia, recurrence and catheter guidance.
  • Clexane Summary of Product CharacteristicsLicensed enoxaparin treatment regimens and pregnancy, renal and reversal information.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom